Ambit Biosciences
About:
Ambit Biosciences, a biopharmaceutical company, develops small molecule kinase inhibitors for cancer and inflammatory disease treatments.
Website: http://www.ambitbio.com
Top Investors: OrbiMed, Horizon Technology Finance, Avalon Ventures, Forward Ventures, Aisling Capital
Description:
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
$216M
$10M to $50M
San Diego, California, United States
2000-01-01
sales(AT)ambitbio.com
Kevin Kinsella
51-100
2012-11-06
Delisted
© 2025 bioDAO.ai